S&P 500   3,853.51 (-1.83%)
DOW   31,544.38 (-1.31%)
QQQ   314.88 (-2.85%)
AAPL   121.89 (-2.76%)
MSFT   230.71 (-1.64%)
FB   258.10 (-2.35%)
GOOGL   2,026.15 (-2.77%)
AMZN   3,089.47 (-2.22%)
TSLA   698.57 (-5.86%)
NVDA   538.26 (-7.19%)
BABA   242.36 (-3.19%)
CGC   33.89 (-4.80%)
GE   12.72 (-3.05%)
MU   89.14 (-3.65%)
NIO   48.11 (-7.23%)
AMD   82.85 (-4.70%)
T   28.72 (-2.25%)
F   11.81 (-3.75%)
ACB   11.15 (-4.21%)
DIS   192.04 (-2.77%)
BA   217.88 (-5.00%)
NFLX   541.46 (-2.16%)
BAC   35.90 (-1.32%)
S&P 500   3,853.51 (-1.83%)
DOW   31,544.38 (-1.31%)
QQQ   314.88 (-2.85%)
AAPL   121.89 (-2.76%)
MSFT   230.71 (-1.64%)
FB   258.10 (-2.35%)
GOOGL   2,026.15 (-2.77%)
AMZN   3,089.47 (-2.22%)
TSLA   698.57 (-5.86%)
NVDA   538.26 (-7.19%)
BABA   242.36 (-3.19%)
CGC   33.89 (-4.80%)
GE   12.72 (-3.05%)
MU   89.14 (-3.65%)
NIO   48.11 (-7.23%)
AMD   82.85 (-4.70%)
T   28.72 (-2.25%)
F   11.81 (-3.75%)
ACB   11.15 (-4.21%)
DIS   192.04 (-2.77%)
BA   217.88 (-5.00%)
NFLX   541.46 (-2.16%)
BAC   35.90 (-1.32%)
S&P 500   3,853.51 (-1.83%)
DOW   31,544.38 (-1.31%)
QQQ   314.88 (-2.85%)
AAPL   121.89 (-2.76%)
MSFT   230.71 (-1.64%)
FB   258.10 (-2.35%)
GOOGL   2,026.15 (-2.77%)
AMZN   3,089.47 (-2.22%)
TSLA   698.57 (-5.86%)
NVDA   538.26 (-7.19%)
BABA   242.36 (-3.19%)
CGC   33.89 (-4.80%)
GE   12.72 (-3.05%)
MU   89.14 (-3.65%)
NIO   48.11 (-7.23%)
AMD   82.85 (-4.70%)
T   28.72 (-2.25%)
F   11.81 (-3.75%)
ACB   11.15 (-4.21%)
DIS   192.04 (-2.77%)
BA   217.88 (-5.00%)
NFLX   541.46 (-2.16%)
BAC   35.90 (-1.32%)
S&P 500   3,853.51 (-1.83%)
DOW   31,544.38 (-1.31%)
QQQ   314.88 (-2.85%)
AAPL   121.89 (-2.76%)
MSFT   230.71 (-1.64%)
FB   258.10 (-2.35%)
GOOGL   2,026.15 (-2.77%)
AMZN   3,089.47 (-2.22%)
TSLA   698.57 (-5.86%)
NVDA   538.26 (-7.19%)
BABA   242.36 (-3.19%)
CGC   33.89 (-4.80%)
GE   12.72 (-3.05%)
MU   89.14 (-3.65%)
NIO   48.11 (-7.23%)
AMD   82.85 (-4.70%)
T   28.72 (-2.25%)
F   11.81 (-3.75%)
ACB   11.15 (-4.21%)
DIS   192.04 (-2.77%)
BA   217.88 (-5.00%)
NFLX   541.46 (-2.16%)
BAC   35.90 (-1.32%)
Log in
NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

Top-Rated Stocks  
$48.00
-0.69 (-1.42 %)
(As of 02/25/2021 01:08 PM ET)
Add
Compare
Today's Range
$47.50
Now: $48.00▼
$50.12
50-Day Range
$46.58
MA: $51.59▼
$54.99
52-Week Range
$30.02
Now: $48.00▼
$58.72
Volume19,837 shs
Average Volume892,966 shs
Market Capitalization$7.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals logo

Headlines

ACADIA Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call Presentation
February 25, 2021 |  seekingalpha.com
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
February 24, 2021 |  nasdaq.com
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 |  finance.yahoo.com
Recap: ACADIA Pharmaceuticals Q4 Earnings
February 24, 2021 |  finance.yahoo.com
Glaucoma Pharmaceuticals Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2025
February 23, 2021 |  marketwatch.com
A Preview Of ACADIA Pharmaceuticals's Earnings
February 23, 2021 |  benzinga.com
Announcing: ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Increased An Energizing 191% In The Last Five Years
February 23, 2021 |  finance.yahoo.com
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
February 19, 2021 |  finance.yahoo.com
Interesting ACAD Put And Call Options For April 1st
February 11, 2021 |  nasdaq.com
Trade Alert: The CEO & Director Of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Stephen Davis, Has Sold Some Shares Recently
February 10, 2021 |  nasdaq.com
Glaucoma Pharmaceuticals Market Analysis, Trends, Growth, Size, Share and Forecast 2019 to 2025
February 9, 2021 |  marketwatch.com
Glaucoma Pharmaceuticals Market Size By Regional Industry Growth, Statistics And Forecast
February 1, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
Previous Symbol
CUSIPN/A
CIK1070494
Webwww.acadia-pharm.com
Phone858-558-2871
Employees580
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio7.95
Quick Ratio7.86

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$339.08 million
Price / Sales22.50
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.54 per share
Price / Book10.57

Profitability

EPS (Most Recent Fiscal Year)($1.60)
Net Income$-235,260,000.00
Net Margins-63.92%
Return on Equity-40.35%
Return on Assets-34.72%

Miscellaneous

Outstanding Shares158,978,000
Market Cap$7.63 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.80 out of 5 stars

Medical Sector

138th out of 1,957 stocks

Pharmaceutical Preparations Industry

61st out of 771 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$48.00
-0.69 (-1.42 %)
(As of 02/25/2021 01:08 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 hold rating, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACADIA Pharmaceuticals stock.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than ACADIA Pharmaceuticals?

Wall Street analysts have given ACADIA Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings data on Tuesday, February, 23rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.05. ACADIA Pharmaceuticals had a negative net margin of 63.92% and a negative trailing twelve-month return on equity of 40.35%.
View ACADIA Pharmaceuticals' earnings history.

How has ACADIA Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD stock has increased by 29.5% and is now trading at $47.76.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ACAD?

16 Wall Street analysts have issued twelve-month price targets for ACADIA Pharmaceuticals' shares. Their forecasts range from $42.00 to $72.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $61.63 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:
  • Mr. Stephen R. Davis, CEO & Director (Age 60, Pay $1.36M)
  • Dr. Srdjan R. Stankovic, Pres (Age 64, Pay $1.23M)
  • Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 41, Pay $689.09k)
  • Mr. Austin D. Kim, Exec. VP, Gen. Counsel & Sec. (Age 57, Pay $700.8k)
  • Mr. James K. Kihara, VP, Corp. Controller & Principal Accounting Officer (Age 41)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
  • Dr. Eliseo Oreste Salinas, Sr. VP, Chief Scientific Officer & Head of External Innovation (Age 65)
  • Mr. Mark C. Johnson, VP of Investor Relations
  • Ms. Stephanie Fagan, Sr. VP of Corp. Affairs & Chief Communications Officer
  • Ms. Charmaine Lykins, Sr. VP of Global Product Planning & Chief Marketing Officer

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include BeiGene (BGNE), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Horizon Therapeutics Public (HZNP), UCB (UCBJF), Catalent (CTLT), CureVac (CVAC), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN) and Teva Pharmaceutical Industries (TEVA).
View all of ACAD's competitors.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (12.25%), Price T Rowe Associates Inc. MD (4.96%), BlackRock Inc. (4.55%), Janus Henderson Group PLC (3.20%), Avoro Capital Advisors LLC (1.23%) and First Trust Advisors LP (1.02%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

Which institutional investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, FMR LLC, Squarepoint Ops LLC, First Trust Advisors LP, Renaissance Technologies LLC, Engineers Gate Manager LP, and Charles Schwab Investment Management Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, James M Daly, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Avidity Partners Management LP, Great Lakes Advisors LLC, Jennison Associates LLC, Artisan Partners Limited Partnership, The Manufacturers Life Insurance Company , Thornburg Investment Management Inc., and Orbimed Advisors LLC.
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $47.76.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $7.59 billion and generates $339.08 million in revenue each year. The biopharmaceutical company earns $-235,260,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 580 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.